

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



Shenzhen International Holdings Limited  
深圳國際控股有限公司  
(Incorporated in Bermuda with limited liability)  
(Stock Code: 00152)

## **(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND (2) CHANGE OF COMPOSITION OF SPECIALISED COMMITTEES OF THE BOARD**

The Board announces that, with effect from 1 February 2022, (i) Dr. Zeng Zhi has been appointed as an Independent Non-executive Director, the chairman of the Audit Committee and a member of the Nomination Committee; and (ii) Mr. Chan King Chung resigned from his position as an Independent Non-executive Director, the chairman the Audit Committee and a member of the Nomination Committee.

### **(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS**

The board of directors (the “**Board**”) of Shenzhen International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from 1 February 2022, (i) Dr. Zeng Zhi (“**Dr. Zeng**”) has been appointed as an independent non-executive director of the Company (the “**Independent Non-executive Director**”), the chairman of the audit committee of the Company (the “**Audit Committee**”) and a member of the nomination committee of the Company (the “**Nomination Committee**”); and (ii) Mr. Chan King Chung (“**Mr. Chan**”) resigned from his position as an Independent Non-executive Director, the chairman of the Audit Committee and a member of the Nomination Committee, as he intends to devote more time to focus on his work commitments.

Mr. Chan has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The biographical details of Dr. Zeng are as follows:

Dr. Zeng, aged 50, holds a Master's degree in Finance from Zhongnan University of Economics and Law, a Master's degree of Applied Business Research and a degree of Doctor of Business Administration from SBS Swiss Business School. He is also a fellow member of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. He has also been awarded the professional qualification certificate in accountancy by the Ministry of Finance of China. Dr. Zeng is currently a chief financial officer of a financial technology company in Hong Kong and a member of the Advisory Board on Accountancy of Lingnan University in Hong Kong. Dr. Zeng was an executive director and chief financial officer of Haike Chemical Group Ltd. (the shares of which were listed on London Stock Exchange ("LSE") (Stock Code: HAIK)), an independent non-executive director of GTS Chemical Holdings Plc (the shares of which were listed on LSE (Stock Code: GTS)), and acted as chief financial officer, company secretary and/or qualified accountant of several companies in China, Hong Kong and Singapore. Dr. Zeng has extensive experience in corporate governance, strategic planning, financial controlling and capital operation.

Dr. Zeng has entered into a service contract with the Company for a term of three years commencing on 1 February 2022 and is subject to retirement by rotation but is eligible for re-election at the annual general meeting of the Company in accordance with the bye-laws of the Company. Dr. Zeng is entitled to receiving an annual director's fee of HK\$350,000, which is determined by the Board based on the recommendation of the remuneration and appraisal committee of the Company with reference to the estimated time to be spent by him on the Company's matters.

Save as disclosed above and as at the date of this announcement, Dr. Zeng:

- (i) does not hold and has not held any directorships in other listed public companies in the last three years;
- (ii) does not hold and has not held any position with the Company and/or its subsidiaries;
- (iii) does not have any relationship with any directors, senior management, substantial shareholders and/or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company; and
- (iv) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Company considers that in relation to the appointment of Dr. Zeng as an Independent Non-executive Director, there is no other information which is discloseable nor is he involved in any of the matters required to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his appointment which needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to extend its heartfelt gratitude to Mr. Chan for his valuable contribution to the Group and would like to welcome Dr. Zeng to the Board.

**(2) CHANGE OF COMPOSITION OF SPECIALISED COMMITTEES OF THE BOARD**

As a result of the change of the composition of the Audit Committee and the Nomination Committee mentioned in (1) above, with effect from 1 February 2022, (i) the Audit Committee will comprise Dr. Zeng (Chairman), Professor Cheng Tai Chiu, Edwin and Mr. Pan Chaojin; and (ii) the Nomination Committee will comprise Mr. Pan Chaojin (Chairman), Mr. Wang Peihang and Dr. Zeng.

By Order of the Board  
**Shenzhen International Holdings Limited**  
**Liu Wangxin**  
*Joint Company Secretary*

28 January 2022

*As at the date of this announcement, the Board consists of Messrs. Li Haitao, Liu Zhengyu, Wang Peihang and Dr. Dai Jingming as executive directors, Mr. Hu Wei and Dr. Zhou Zhiwei as non-executive directors and Professor Cheng Tai Chiu, Edwin, Messrs. Pan Chaojin and Chan King Chung as independent non-executive directors.*